Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 3/20 | 0.63 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.52 |
| ▸ | PRKACA | P17612 | 4/20 | 0.52 |
| ▸ | PRKCQ | Q04759 | 4/20 | 0.52 |
| ▸ | JAK2 | O60674 | 3/20 | 0.52 |
| ▸ | PAK4 | O96013 | 3/20 | 0.52 |
| ▸ | LTK | P29376 | 3/20 | 0.52 |
| ▸ | GRK5 | P34947 | 3/20 | 0.52 |
| ▸ | CLK2 | P49760 | 3/20 | 0.52 |
| ▸ | CDK7 | P50613 | 3/20 | 0.52 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.52 |
| ▸ | PRKX | P51817 | 3/20 | 0.52 |
| ▸ | MST1R | Q04912 | 3/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.52 |
| ▸ | CAMK2A | Q9UQM7 | 3/20 | 0.52 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.52 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.52 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29702872 | 0.84 | NUDT1 (0.60) | NUDT1PRKD3PRKACAPRKCQJAK2 | |
| SCHEMBL1456822 | 0.84 | NUDT1 (0.60) | NUDT1PRKD3PRKACAPRKCQJAK2 | |
| SCHEMBL29702772 | 0.83 | NUDT1 (0.73) | NUDT1PRKD3PRKACAPRKCQJAK2 | |
| SCHEMBL1951650 | 0.83 | NUDT1 (0.73) | NUDT1PRKD3PRKACAPRKCQJAK2 | |
| SCHEMBL12605418 | 0.83 | NUDT1 (0.60) | NUDT1PRKD3PRKACAPRKCQJAK2 | |
| SCHEMBL2606616 | 0.82 | NUDT1 (0.66) | NUDT1PRKD3PRKACAPRKCQJAK2 | |
| SCHEMBL30808539 | 0.82 | NUDT1 (0.66) | NUDT1PRKD3PRKACAPRKCQJAK2 | |
| SCHEMBL12605423 | 0.81 | NUDT1 (0.58) | NUDT1PRKD3PRKACAPRKCQJAK2 | |
| Acetic Acid SCHEMBL28045105 | 0.81 | NUDT1 (0.55) | NUDT1PRKD3PRKACAPRKCQJAK2 | |
| SCHEMBL15645275 | 0.81 | NUDT1 (0.57) | NUDT1PRKD3PRKACAPRKCQJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025061029-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | 3H PHARMACEUTICALS CO., LTD. (CN) | 2025-03-27 | — | — | WO | disclosed |
| WO-2023015156-A1 | PYRROLOPYRIDINE-3- AND 4-CARBOXAMIDE COMPOSITIONS AND METHODS FOR CELLULAR PROLIFERATION | HUDSPETH A JAMES (US) | 2023-02-09 | — | — | WO | disclosed |
| EP-3589618-B1 | PYRAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2022-12-28 | — | — | EP | disclosed |
| WO-2018158212-A1 | PYRAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-09-07 | — | — | WO | disclosed |
| CN-101218241-B | Pyrrolopyridine derivatives as protein kinase inhibitors | IRM LLC | 2011-02-16 | — | — | CN | disclosed |
| EP-1896470-B1 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-05-26 | — | — | EP | disclosed |
| EP-1896470-B1 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-05-26 | — | — | EP | disclosed |
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2008-12-04 | — | — | US | disclosed |
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2008-12-04 | — | — | US | disclosed |
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2008-12-04 | — | — | US | disclosed |
| CN-101218241-A | Pyrrolopyridine derivatives as protein kinase inhibitors | IRM LLC (BM) | 2008-07-09 | — | — | CN | disclosed |
| WO-2008049994-A1 | NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN CHAPERONE HSP 90 | SANOFI-AVENTIS (FR) | 2008-05-02 | — | — | WO | disclosed |
| EP-1896470-A2 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006124863-A2 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | ERBB2, JAK2, AURKC | NUDT1 3955/4885PRKD3 153/4885PRKACA 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.